Drug intelligence / Profile preview

MGY1838-IBD

Development stage: Preclinical
Lead developer: IMMUNISBIO
Modality: Cell Therapies
Administration: Intravenous

Overview

MGY1838-IBD is an autologous regulatory T cell (Treg) therapy being developed by IMMUNISBIO for the treatment of inflammatory bowel disease (IBD). Regulatory T cells are a specialized subset of T lymphocytes that maintain immune tolerance and prevent autoimmune responses by suppressing the activity of effector T cells and other inflammatory cells. By utilizing the patient's own Tregs, MGY1838-IBD aims to mitigate the chronic inflammation characteristic of IBD and restore immune balance within the gastrointestinal tract. The program is currently in the IND-enabling stage of development.

Beyond the preview

Go deeper on MGY1838-IBD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MGY1838-IBD.

Explore the full profile